Acute, transitional and long-term cluster headache treatment: pharmacokinetic issues

References

• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.
   PubMed Web of Science ®Google Scholar
• Leroux E, Ducros A. Cluster headache. Orphanet J Rare Disord. doi:10.1186/1750-1172-3-20.
   Web of Science ®Google Scholar
• Mitsikostas DD, Edvinsson L, Jensen RH, et al. Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation. J Headache Pain. doi:10.1186/1129-2377-15-79.
   Web of Science ®Google Scholar
• May A, Leone M, Áfra J, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol. 2006;13:1066–1077.
   PubMed Web of Science ®Google Scholar
• Rolan PE. Drug interactions with triptans : which are clinically significant? CNS Drugs. 2012;26:949–957.
   PubMed Web of Science ®Google Scholar
• Miksys S, Tyndale RF. Cytochrome P450-mediated drug metabolism in the brain. J Psychiatry Neurosci. 2013;38:152–163.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC, Jensen RH. Management of cluster headache. CNS Drugs. 2012;26:571–580.
   PubMed Web of Science ®Google Scholar
• Martelletti P. Cluster headache management and beyond. Expert Opin Pharmacother. 2015;16:1–5.
   PubMed Web of Science ®Google Scholar
• Gooriah R, Buture A, Ahmed F. Evidence-based treatments for cluster headache. Ther Clin Risk Manag. 2015;11:1687–1696.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Mitsikostas D. Cluster headache : a quasi rare disorder needing a reappraisal. J Headache Pain. 2015;16:15–16.
   PubMed Web of Science ®Google Scholar
• May A. Cluster headache: pathogenesis, diagnosis, and management. Lancet. 2005;366:843–855.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Tfelt-Hansen J. Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009;49:117–125.
   PubMed Web of Science ®Google Scholar
• Weaver-Agostoni J. Cluster headache. Am Fam Physician. 2013;88:122–128.
   PubMed Web of Science ®Google Scholar
• Kivistö KT, Neuvonen PJ, Tarssanen L. Pharmacokinetics of verapamil in overdose. Hum Exp Toxicol. 1997;16:35–37.
   PubMed Web of Science ®Google Scholar
• Morel N, Buryi V, Feron O, et al. The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998;125:1005–1012.
   PubMed Web of Science ®Google Scholar
• Busse D, Templin S, Mikus G, et al. Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study. Eur J Clin Pharmacol. 2006;62:613–619.
   PubMed Web of Science ®Google Scholar
• Sternieri E, Coccia CPR, Pinetti D, et al. Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opin Drug Metab Toxicol. 2006;2:981–1007.
   PubMed Web of Science ®Google Scholar
• Pillai U, Muzaffar J, Sen S, et al. Grapefruit juice and verapamil: a toxic cocktail. South Med J. 2009;102:308–309.
   PubMed Web of Science ®Google Scholar
• Wang Y, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004;32:259–266.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Wainer IW, Anacleto AI. Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration. Drug Metab Dispos. 2000;28:760–765.
   PubMed Web of Science ®Google Scholar
• Lemma GL, Wang Z, Hamman MA, et al. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther. 2006;79:218–230.
   PubMed Web of Science ®Google Scholar
• Dubovsky SL, Franks RD, Allen S. Verapamil: a new antimanic drug with potential interactions with lithium. J Clin Psychiatry. 1987;48:371–372.
   PubMed Web of Science ®Google Scholar
• Ledwitch KV, Barnes RW, Roberts AG. Unravelling the complex drug-drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein. Biosci Rep. 2016;36:e00309–e00309.
   Google Scholar
• Lambert Kuhn E, Levêque D, Lioure B, et al. Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report. J Clin Pharm Ther. 2016;41:104–105.
   PubMed Web of Science ®Google Scholar
• Yeo KR, Yeo WW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol. 2001;51:461–470.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Prograf®, tacrolimus capsules and injection prescribing information [Internet]. May 2015. [cited 2016 May 24]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050708s045,050709s038lbl.pdf
   Google Scholar
• Stein CM, Ch B. Oral erythromycin and the risk of sudden death from cardiac causes. Nejm. 2004;351(11):1089–1096.
   PubMed Web of Science ®Google Scholar
• Reed M, Wall GC, Shah NP, et al. Verapamil toxicity resulting from a probable interaction with telithromycin. Ann Pharmacother. 2005;39:357–360.
   PubMed Web of Science ®Google Scholar
• Lamberg TS, Kivistö KT, Neuvonen PJ. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin Pharmacol Ther. 1998;63:640–645.
   PubMed Web of Science ®Google Scholar
• Summers MA, Moore JL, McAuley JW. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother. 2004;38:1631–1634.
   PubMed Web of Science ®Google Scholar
• Maggio TG, Bartels DW. Increased cyclosporine blood concentrations due to verapamil administration. Drug Intell Clin Pharm. 1988;22:705–707.
   PubMedGoogle Scholar
• Wing LMH, Miners JO, Lillywhite KJ. Verapamil disposition – effects of sulphinpyrazone and cimetidine. Br J Clin Pharmacol. 1985;19:385–391.
   PubMed Web of Science ®Google Scholar
• Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981;64:437–442.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Knox C, Guo AC, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34:D668–D672.
   PubMed Web of Science ®Google Scholar
• Sternieri E, Coccia CPR, Pinetti D, et al. Pharmacokinetics and interactions of headache medications, part I: introduction, pharmacokinetics, metabolism and acute treatments. Expert Opin Drug Metab Toxicol. 2006;2:961–979.
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Mamdani MM, Kopp A, et al. Drug-induced lithium toxicity in the elderly: a population-based study. J Am Geriatr Soc. 2004;52:794–798.
   PubMed Web of Science ®Google Scholar
• Van Wyk M, Sommers DK, Moncrieff J. Effects of enhancement and antagonism of 5-hydroxytryptamine activity on the influence of metoclopramide on gastric emptying. Digestion. 1993;54:40–43.
   PubMed Web of Science ®Google Scholar
• Rosenfeld WE, Doose DR, Walker SA, et al. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia. 1997;38:317–323.
   PubMed Web of Science ®Google Scholar
• Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol. 2000;14:301–319.
   PubMed Web of Science ®Google Scholar
• Bailey DG, Dresser G, Arnold JMO. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? CMAJ. 2013;185:309–316.
   PubMed Web of Science ®Google Scholar
• Satoh T, Watanabe Y, Ikarashi N, et al. Effects of Kampo medicines on P-glycoprotein. Biol Pharm Bull. 2009;32:2018–2021.
   PubMed Web of Science ®Google Scholar
• Bauer LA, Schumock G, Horn J, et al. Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. Clin Pharmacol Ther. 1992;52:6–10.
   PubMed Web of Science ®Google Scholar
• Perez-Reyes M, White WR, Hicks RE. Interaction between ethanol and calcium channel blockers in humans. Alcohol Clin Exp Res. 1992;16:769–775.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Schwedt T. Cluster headache-acute and prophylactic therapy. Headache. 2011;51:272–286.
   PubMed Web of Science ®Google Scholar
• Becker WJ. Cluster headache: conventional pharmacological management. Headache. 2013;53:1191–1196.
   PubMed Web of Science ®Google Scholar
• Gaul C, Diener H-C, Müller OM. Cluster headache: clinical features and therapeutic options. Dtsch Arztebl Int. 2011;108:543–549.
   PubMed Web of Science ®Google Scholar
• Lozano R, Marín R, Santacruz M-J. Influence of hypothyroidism on renal function of lithium-treated patients. Neuropsychiatr Dis Treat. 2015;25–27.
   Web of Science ®Google Scholar
• Shine B, McKnight RF, Leaver L, et al. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet (London, England). 2015;386:461–468.
   PubMed Web of Science ®Google Scholar
• Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet. 1995;29:172–191.
   PubMed Web of Science ®Google Scholar
• Goadsby P, Tfelt-Hansen P. Cluster headache: introduction and epidemiology. In: Olesen J, Goadsby P, Ramadan N, et al., editors. The headaches. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2006. p. 743–745.
   Google Scholar
• Lainez MJA, Pascual J, Pascual AM, et al. Topiramate in the prophylactic treatment of cluster headache. Headache. 2003;43:784–789.
   PubMed Web of Science ®Google Scholar
• Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet. 1996;31:29–46.
   PubMed Web of Science ®Google Scholar
• Porter R, Meldrum B. Drugs that act in the central nervous system. In: Katzung B, Masters S, Trevor A, editors. Basic and clinical pharmacology. 12th ed. San Francisco (CA): McGraw-Hill; 2012. p. 403–428.
   Google Scholar
• Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs. 2002;16:263–272.
   PubMed Web of Science ®Google Scholar
• Forde G, Duarte RA, Rosen N. Managing chronic headache disorders. Med Clin North Am. 2016;100:117–141.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Magnoux E, Dobson CF, et al. Melatonin as adjunctive therapy in the prophylaxis of cluster headache: a pilot study. Headache. 2002;42:787–792.
   PubMed Web of Science ®Google Scholar
• El Amrani M, Massiou H, Bousser MG. A negative trial of sodium valproate in cluster headache: methodological issues. Cephalalgia. 2002;22:205–208.
   PubMed Web of Science ®Google Scholar
• Schuh-Hofer S, Israel H, Neeb L, et al. The use of gabapentin in chronic cluster headache patients refractory to first-line therapy. Eur J Neurol. 2007;14:694–696.
   PubMed Web of Science ®Google Scholar
• Hering R, Kuritzky A. Sodium valproate in the treatment of cluster headache: an open clinical trial. Cephalalgia. 1989;9:195–198.
   PubMed Web of Science ®Google Scholar
• Gallagher RM, Mueller LL, Freitag FG. Divalproex sodium in the treatment of migraine and cluster headaches. J Am Osteopath Assoc. 2002;102:92–94.
   PubMedGoogle Scholar
• Leone M, D’Amico D, Moschiano F, et al. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia. 1996;16:494–496.
   PubMed Web of Science ®Google Scholar
• Katzung B. Histamine, serotonin, & the ergot alkaloids. In: Katzung B, Masters S, Trevor A, editors. Basic and clinical pharmacology 12th ed. San Francisco (CA): McGraw-Hill; 2012. p. 273–294.
   Google Scholar
• Neeb L, Anders L, Euskirchen P, et al. Corticosteroids alter CGRP and melatonin release in cluster headache episodes. Cephalalgia. 2015;35:317–326.
   PubMed Web of Science ®Google Scholar
• Varis T, Kivistö KT, Backman JT, et al. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther. 2000;68:487–494.
   PubMed Web of Science ®Google Scholar
• Preissner S, Kroll K, Dunkel M, et al. SuperCYP: a comprehensive database on cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2009;38:237–243.
   PubMed Web of Science ®Google Scholar
• Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest. 1997;99:2545–2553.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Emend®, aprepitant capsules prescribing information [Internet]. August 2014. [cited 2016 May 18]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021549s024lbl.pdf
   Google Scholar
• Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol. 2001;51:443–450.
   PubMed Web of Science ®Google Scholar
• Young MC, Hughes IA. Loss of therapeutic control in congenital adrenal hyperplasia due to interaction between dexamethasone and primidone. Acta Paediatr Scand. 1991;80:120–124.
   PubMed Web of Science ®Google Scholar
• Baciewicz AM, Baciewicz FA. Cyclosporine pharmacokinetic drug interactions. Am J Surg. 1989;157:264–271.
   PubMed Web of Science ®Google Scholar
• Fost DA, Leung DY, Martin RJ, et al. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. J Allergy Clin Immunol. 1999;103:1031–1035.
   PubMed Web of Science ®Google Scholar
• Frey BM, Schaad HJ, Frey FJ. Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. Eur J Clin Pharmacol. 1984;26:505–511.
   PubMed Web of Science ®Google Scholar
• Keilholz U, Guthrie GPJ. Adverse effect of phenytoin on mineralocorticoid replacement with fludrocortisone in adrenal insufficiency. Am J Med Sci. 1986;291:280–283.
   PubMed Web of Science ®Google Scholar
• Carrie F, Roblot P, Bouquet S, et al. Rifampin-induced nonresponsiveness of giant cell arteritis to prednisone treatment. Arch Intern Med. 1994;154:1521–1524.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Norvir®, ritonavir capsules and oral solution prescribing information [Internet]. November 2011. [cited 2016 Apr 25]. Available from: www.access.data.fda.gov/drugsatfda_docs/label/2011/020945s032lbl.pdf
   Google Scholar
• Honoré PM, Jacobs R, De Waele E, et al. What do we know about steroids metabolism and “PK/PD approach” in AKI and CKD especially while on RRT – current status in 2014. Blood Purif. 2014;38:154–157.
   PubMed Web of Science ®Google Scholar
• Oka A, Oda M, Saitoh H, et al. Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002;25:393–396.
   PubMed Web of Science ®Google Scholar
• Kawada S, Kashihara K, Imamura T, et al. High-dose intravenous methylprednisolone for the prophylactic treatment of cluster headache. Springerplus. 2013;2:156–159.
   PubMed Web of Science ®Google Scholar
• Pareja JA, Álvarez M. The usual treatment of trigeminal autonomic cephalalgias. Headache. 2013;53:1401–1414.
   PubMed Web of Science ®Google Scholar
• Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1990;19:126–146.
   PubMed Web of Science ®Google Scholar
• Antonaci F, Costa A, Candeloro E, et al. Single high-dose steroid treatment in episodic cluster headache. Cephalalgia. 2005;25:290–295.
   PubMed Web of Science ®Google Scholar
• Zhou S-F, Zhou Z-W, Yang L-P, et al. Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16:3480–3675.
   PubMed Web of Science ®Google Scholar
• Leroux E, Valade D, Taifas I, et al. Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10:891–897.
   PubMed Web of Science ®Google Scholar
• Lambru G, Abu Bakar N, Stahlhut L, et al. Greater occipital nerve blocks in chronic cluster headache: a prospective open-label study. Eur J Neurol. 2014;21:338–343.
   PubMed Web of Science ®Google Scholar
• Ambrosini A, Vandenheede M, Rossi P, et al. Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: a double-blind placebo-controlled study. Pain. 2005;118:92–96.
   PubMed Web of Science ®Google Scholar
• Cohen AS, Burns B, Goadsby P. High-flow oxygen for treatment of cluster headache. JAMA. 2009;302:2451–2457.
   PubMed Web of Science ®Google Scholar
• Rozen TD. Inhaled oxygen for cluster headache: efficacy, mechanism of action, utilization, and economics. Curr Pain Headache Rep. 2012;16:175–179.
   Web of Science ®Google Scholar
• Petersen AS, Barloese MC, Lund NL, et al. Oxygen therapy for cluster headache. A mask comparison trial. A single-blinded, placebo-controlled, crossover study. Cephalalgia. 2016;0:1–11.
   Google Scholar
• Evers S, Rapoport A. The use of oxygen in cluster headache treatment worldwide – a survey of the International Headache Society (IHS). Cephalalgia. 2016;0:1–3.
   Google Scholar
• Oude Nijhuis JC, Haane DY, Koehler PJ. A review of the current and potential oxygen delivery systems and techniques utilized in cluster headache attacks. Cephalalgia. 2015;0:1–10.
   Google Scholar
• Leone M, Proietti Cecchini A. Long-term use of daily Sumatriptan injections in severe drug-resistant chronic cluster headache. Neurology. 2016;86:194–195.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Bordini CA, Antoniazzi AL, et al. The triptan formulations: a critical evaluation. Arq Neuropsiquiatr. 2003;61:313–320.
   PubMed Web of Science ®Google Scholar
• Lionetto L, Negro A, Casolla B, et al. Sumatriptan succinate : pharmacokinetics of different formulations in clinical practice. Expert Opin Pharmacother. 2012;13:2369–2380.
   PubMed Web of Science ®Google Scholar
• Dixon CM, Park GR, Tarbit MH. Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol. 1994;47:1253–1257.
   PubMed Web of Science ®Google Scholar
• Fox AW. Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect: research submission. Headache. 2010;50:249–255.
   PubMed Web of Science ®Google Scholar
• Matthaei J, Kuron D, Faltraco F, et al. OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2015;00:n/a–n/a.
   Google Scholar
• Cittadini E, May A, Straube A, et al. Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. Arch Neurol. 2006;63:1537–1542.
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Mathew NT, Silberstein SD, et al. Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study. Neurology. 2007;69:821–826.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Yates R. Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy. Headache. 2006;46:138–149.
   PubMed Web of Science ®Google Scholar
• Yates RA, Tateno M, Nairn K, et al. The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects. Eur J Clin Pharmacol. 2002;58:247–252.
   PubMed Web of Science ®Google Scholar
• Wild MJ, McKillop D, Butters CJ. Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan. Xenobiotica. 1999;29:847–857.
   PubMed Web of Science ®Google Scholar
• Lionetto L, Casolla B, Mastropietri F, et al. Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines. Expert Opin Drug Metab Toxicol. 2012;8:1043–1050.
   PubMed Web of Science ®Google Scholar
• Flockhart D Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine [cited 2016 Jan 28]. Available from: http://medicine.iupui.edu/clinpharm/ddis/clinical-table/.
   Google Scholar
• Seaber EJ, Peck RW, Smith DA, et al. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. Br J Clin Pharmacol. 1998;46:433–439.
   PubMed Web of Science ®Google Scholar
• Francis GJ, Becker WJ, Pringsheim TM. Acute and preventive pharmacologic treatment of cluster headache. Neurology. 2010;75:463–473.
   PubMed Web of Science ®Google Scholar
• Prakash S, Shah ND, Chavda BV. Cluster headache responsive to indomethacin: case reports and a critical review of the literature. Cephalalgia. 2010;30:975–982.
   PubMed Web of Science ®Google Scholar
• Antonaci F, Costa A, Ghirmai S, et al. Parenteral indomethacin (the INDOTEST) in cluster headache. Cephalalgia. 2003;23:193–196.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Giamberardino MA, Mitsikostas D-D. Greater occipital nerve as target for refractory chronic headaches: from corticosteroid block to invasive neurostimulation and back. Expert Rev Neurother. 2016;7175:1–2.
   Google Scholar